Exelixis (EXEL) Non-Current Assets (2010 - 2026)
Exelixis (EXEL) posted quarterly Non-Current Assets of $1.4 billion for Q2 2026, down 3.87% year-over-year from $1.4 billion in Q2 2025, and down 1.15% quarter-over-quarter from $1.4 billion in Q1 2026.
Exelixis (EXEL) Non-Current Assets (2010 - 2026) Analysis & Trends
Exelixis' Non-Current Assets history runs 17 years deep, the most recent figure standing at $1.4 billion for Q2 2026.
- In Q2 2026, Non-Current Assets fell 3.87% year-over-year to $1.4 billion; the TTM figure through Apr 2026 stood at $5.7 billion (up 1.38% YoY), while the FY2026 annual figure was $1.4 billion, down 5.34% from the prior year.
- Non-Current Assets for Q2 2026 stood at $1.4 billion, down from $1.4 billion in the prior quarter.
- The five-year high for Non-Current Assets was $1.6 billion in Q4 2023, with the low at $811.4 million in Q2 2022.
- The 5-year median for Non-Current Assets is $1.4 billion (2025), against an average of $1.4 billion.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets soared 85.89% in 2022, then dropped 16.51% in 2024.
- Exelixis' Non-Current Assets stood at $1.5 billion in 2022, then increased by 11.82% to $1.6 billion in 2023, then retreated by 13.16% to $1.4 billion in 2024, then advanced by 0.76% to $1.4 billion in 2025, then retreated by 2.56% to $1.4 billion in 2026.
- Business Quant data shows EXEL's Non-Current Assets at $1.4 billion in Q2 2026, $1.4 billion in Q1 2026, and $1.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | 1.24 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | 1.24 Bn |
| Apr 3, 2026 | 1.38 Bn |
| Jan 2, 2026 | 1.40 Bn |
| Oct 3, 2025 | 1.42 Bn |
| Jul 4, 2025 | 1.50 Bn |
| Apr 4, 2025 | 1.44 Bn |
| Jan 3, 2025 | 1.48 Bn |
| Sep 27, 2024 | 1.41 Bn |
| Jun 28, 2024 | 1.30 Bn |
| Mar 29, 2024 | 1.51 Bn |
| Dec 29, 2023 | 1.62 Bn |
| Sep 29, 2023 | 1.53 Bn |
| Jun 30, 2023 | 1.55 Bn |
| Mar 31, 2023 | 1.51 Bn |
| Dec 30, 2022 | 1.45 Bn |
| Sep 30, 2022 | 1.12 Bn |
| Jul 1, 2022 | 1.03 Bn |
| Apr 1, 2022 | 811.38 Mn |
| Dec 31, 2021 | 781.49 Mn |
| Oct 1, 2021 | 785.71 Mn |